D. E. Shaw & Co., Inc. - IBERE PHARMACEUTICALS ownership

IBERE PHARMACEUTICALS's ticker is IBER and the CUSIP is G46843101. A total of 1 filers reported holding IBERE PHARMACEUTICALS in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of IBERE PHARMACEUTICALS
ValueSharesWeighting
Q4 2022$1,513,500
-44.5%
150,000
-45.5%
0.00%
-33.3%
Q3 2022$2,725,000
+1.0%
275,008
+0.0%
0.00%0.0%
Q2 2022$2,697,000
+58.9%
274,908
+58.9%
0.00%
+50.0%
Q1 2022$1,697,000
-56.8%
172,962
-57.2%
0.00%
-33.3%
Q4 2021$3,929,000
+151.1%
404,176
+150.2%
0.00%
+200.0%
Q3 2021$1,565,000
+546.7%
161,539
+546.2%
0.00%
Q2 2021$242,00025,0000.00%
Other shareholders
IBERE PHARMACEUTICALS shareholders Q1 2023
NameSharesValueWeighting ↓
Ampfield Management, L.P. 44,543$431,0000.35%
MANGROVE PARTNERS IM, LLC 200,000$1,934,0000.20%
SPRING CREEK CAPITAL LLC 400,000$3,868,0000.19%
Vestcor Inc 400,000$3,868,0000.13%
KNOTT DAVID M 36,000$348,0000.12%
Radcliffe Capital Management, L.P. 300,000$2,901,0000.09%
Hudson Bay Capital Management LP 621,750$6,012,0000.07%
BERKLEY W R CORP 68,776$666,0000.07%
PICTON MAHONEY ASSET MANAGEMENT 200,000$1,934,0000.06%
Polar Asset Management Partners Inc. 500,000$4,835,0000.05%
View complete list of IBERE PHARMACEUTICALS shareholders